pharmacology
Fundamental Classifications and Definitions of Drugs
In the study of pharmacology, drugs are categorized based on their intended use, regulatory status, and quality characteristics. Orphan drugs are agents used specifically for the treatment of rare diseases. These drugs often face challenges regarding profitability due to the small patient population they serve. In contrast, essential drugs are formulated to meet the healthcare needs of the majority of a population. To be classified as essential, a drug must be inexpensive, easily available, efficacious, and safe. They are typically administered as a single molecule rather than a fixed-dose combination. Prescription or legend drugs are those that strictly require a medical prescription and fall under Schedule H regulations.
Regulatory pharmacology also defines drugs by their manufacturing and labeling integrity. Spurious drugs are those where the drug component is falsified, resulting in a failure to produce the expected therapeutic effect. Misbranded drugs contain incorrect or missing information on the label, though they may still produce an adequate therapeutic effect. Adulterated drugs contain unwanted additives; a notable example is cough syrup contaminated with diethylene glycol, which can lead to renal failure. Clinicians also utilize the concept of the P-drug, or Personal drug, which is chosen for a specific disease based on the STEP criteria: Safety, Tolerability, Efficacy, and low Price. Finally, Rational Drug Use is defined as the administration of the right drug for the right disease and patient, at the right dose, duration, and route, with proper dispensation and monitoring. Notably, the concept of a "right price" is excluded from this formal definition.
Pharmacokinetics: Principles of Drug Absorption and Bioavailability
Pharmacokinetics describes the movement of a drug through the body, often summarized by the acronym ADME: Absorption, Distribution, Metabolism, and Excretion. Passive diffusion is identified as the most common mechanism for drug movement. Diffusion is significantly increased for unionized drugs because they possess higher lipid solubility; this state is achieved when the pH of the drug and the medium are identical. The maximum absorption of most drugs occurs in the small intestine due to its large surface area. A critical parameter is the , defined as the pH at which a drug exists in a state of ionization and unionization.
Oral absorption is measured by its extent and rate. The extent of absorption, or bioavailability (), represents the fraction of the drug that reaches systemic circulation. It is calculated using the formula . Bioavailability ranges from to , with IV and inhalational gases achieving () bioavailability. Factors affecting this include the first-pass metabolism and the inherent absorption characteristics of the drug. Drugs with small molecular size and high lipid solubility exhibit good oral absorption, whereas large proteins, such as those ending in "-tide" (Octreotide), "-ase" (Asparaginase), or "-mab" (Trastuzumab), show poor oral absorption. The rate of absorption is the amount absorbed per unit of time, determined by the (time to achieve maximum plasma concentration, or ). The inhalational route provides the fastest rate of absorption.
Drug Distribution and Plasma Protein Dynamics
Once absorbed, drugs distribute between the systemic circulation and various tissues or organs, such as adipose tissue. The apparent Volume of Distribution () is a theoretical volume that relates the amount of drug in the body to the concentration measured in the plasma. It is calculated as , where is the IV dose and is the initial plasma concentration. A high () indicates high extravascular concentration, while a low () suggests the drug is largely confined to the intravascular space. The is essential for calculating the Loading Dose (), which is the dose required to rapidly achieve a target plasma concentration (). For IV administration, , and for other routes, . High drugs are not effectively removed by dialysis; examples include benzodiazepines (antidote: flumazenil), beta-blockers (antidote: glucagon), amphetamines (antidote: ammonium chloride), digoxin (antidote: Digibind), opioids (antidote: naloxone), organophosphates (antidote: atropine), and calcium channel blockers (antidote: calcium gluconate).
Drug distribution is also influenced by plasma protein binding. Albumin is the most common protein and binds primarily to acidic drugs like aspirin, warfarin, and sulfonamides. Alpha-1-acid glycoprotein binds to basic drugs such as opioids, tricyclic antidepressants, beta-blockers, and anti-arrhythmics like amiodarone and lidocaine. Hypoalbuminemia, caused by decreased synthesis in cirrhosis or increased excretion in nephrotic syndrome and diabetes, results in decreased drug binding. This leads to increased free drug levels and potential toxicity OR increased excretion and drug failure depending on the specific drug's properties.
Biotransformation: Mechanisms of Drug Metabolism
Metabolism involves two primary phases. Phase I, or the breakdown phase, involves the addition of functional groups through reactions like oxidation (the most common), reduction, cyclization, and hydrolysis. These reactions are largely mediated by Cytochrome P450 enzymes (CYP450), specifically the gene isoform CYP3A4. Phase II, or conjugation, involves adding a negatively charged conjugate to the functional group to make the drug ionized and water-soluble for excretion. Glucuronidation is the most common Phase II reaction, mediated by glucuronyl transferase (GT). Patients with Crigler-Najjar syndrome have decreased GT, leading to increased toxicity of drugs like irinotecan and atazanavir.
Clinically significant drug-enzyme interactions occur with enzyme inducers and inhibitors. Enzyme inducers, remembered by the mnemonic "GRAB PC" (Griseofulvin, Rifampicin, Alcohol-chronic, Benzopyrene, Phenytoin/Phenobarbital/Primidone, Carbamazepine/Cigarettes), cause drug failure. For example, rifampicin can cause oral contraceptive (OCP) failure and is contraindicated in HIV-TB co-infection unless the dose of dolutegravir is doubled. Enzyme inhibitors, remembered by "QuICK VEG, Disk" (Quinidine, Isoniazid/Protease inhibitors, Cimetidine/Chloramphenicol/Ciprofloxacin, Ketoconazole/Itraconazole/Fluconazole, Valproate, Erythromycin, Grapefruit juice, Disulfiram/Delavirdine/DEC), cause drug toxicity. Examples include erythromycin causing theophylline toxicity and clarithromycin causing statin toxicity. Additionally, drugs metabolized by plasma esterase (e.g., procaine, esmolol, remifentanil, succinylcholine) have very short half-lives due to rapid metabolism.
Pharmacokinetics of Drug Excretion and Elimination
The kidney is the primary organ for drug excretion. Excretion efficiency is increased when the drug is ionized and water-soluble, which occurs when there is a difference between the pH of the drug and the urine medium. In cases of acidic drug toxicity (Aspirin, Phenobarbital), urinary alkalinization with bicarbonate is performed. For basic drug toxicity (Amphetamines), acidification with ammonium chloride is used. The mechanisms include filtration (20% of clearance, involving only free drug) and tubular secretion (80% of clearance, involving both free and protein-bound drug).
To maintain a steady-state plasma concentration (SSPC), the infusion rate () must equal the rate of drug elimination. The formula is . Maintenance dose () is calculated as . Half-life () is determined by the formula . SSPC is typically achieved after 5 half-lives, at which point Therapeutic Drug Monitoring (TDM) should begin. Elimination follows either zero-order kinetics (constant amount eliminated per hour, e.g., alcohol, phenytoin, heparin) or first-order kinetics (constant proportion eliminated per hour, which applies to most other drugs).
Pharmacodynamics: Dose-Response and Receptor Interactions
Pharmacodynamics is the study of drug-induced changes via targets, summarized as Drug Receptor Effect (DRE). Essential parameters include affinity (tendency to bind), efficacy (maximum effect produced, the most important factor), and potency (relative dose required). On a Graded Dose-Response Curve (DRC), efficacy is represented by the height of the curve, while potency is shown by a left shift (lower dose for same effect). On a Quantal DRC, which measures population response, we identify the (effective dose for ), (toxic dose for ), and (lethal dose for in animals). The Therapeutic Index () is a marker of safety, calculated as for humans.
Drug-receptor interactions include various forms of antagonism. Physical antagonism involves binding (e.g., charcoal adsorbing alcohol), while chemical antagonism involves neutralization (e.g., protamine sulphate neutralizing heparin). Physiological antagonism occurs at different receptors (e.g., histamine causing bronchoconstriction via and adrenaline causing bronchodilation via ). Competitive antagonism is often reversible and causes a right shift in the DRC (efficacy remains constant, but increases and potency decreases). Non-competitive antagonism is irreversible and decreases the height/efficacy of the DRC.
Development and Safety: Clinical Trials and Regulatory Schedules
Drug development starts with pre-clinical trials on animals before moving to human clinical trials. Phase 0 involves microdosing () to assess pharmacokinetics. Phase I focuses on safety, toxicity, and maximum tolerable dose in to healthy volunteers. Phase II is an efficacy trial involving to patients to determine the dose range. Phase III is a confirmatory trial in to patients across multiple centers, leading to drug marketing approval by bodies like the FDA or CDSCO. Phase IV is post-marketing surveillance for rare or long-term adverse reactions. Phase V involves pharmacoepidemiology studies.
Regulatory schedules define the handling of drugs. Schedule G requires medical supervision, Schedule H requires a prescription, and Schedule H1 (containing antibiotics) is marked by a red "Rx". Schedule X covers narcotics and psychotropic drugs with high abuse potential, requiring a red "XRx" label and the retention of prescription copies for two years. Pregnancy categories range from A (safe) to X (teratogenic, e.g., thalidomide causing phocomelia). Category D includes drugs like valproate, where benefits may outweigh risks despite known teratogenicity (neural tube defects).
Adverse Drug Reactions and Pharmacovigilance
Adverse Drug Reactions (ADRs) are classified using the "ABCDEF" mnemonic. Type A (Augmented) is dose-dependent and related to the drug's effect (e.g., antihypertensives causing hypotension). Type B (Bizarre) is dose-independent and hypersensitive (e.g., penicillin allergy). Type C (Chronic) is both dose and duration dependent (e.g., Cushing syndrome from steroids). Type D (Delayed) occurs long after exposure (e.g., teratogenicity). Type E (End-of-use) involves withdrawal symptoms (e.g., opioid withdrawal). Type F (Failure) occurs due to interactions like enzyme induction.
Pharmacovigilance is the system for monitoring these reactions. ADR information flows from the patient/hospital to the "VIGIFLOW" software, then to the National Coordinating Centre (IPC Ghaziabad), which forms a report for the CDSCO (New Delhi). This data is ultimately sent to the International Pharmacovigilance Centre in Sweden (Uppsala), which maintains "Vigibase," the world's largest database, and decides on drug bans.
Pharmacogenetics and Individualized Drug Response
Pharmacogenetics studies how genetic polymorphism influences drug response. Acetyltransferase polymorphism involves the NAT genes; fast acetylators (NAT 1) show decreased effect, while slow acetylators (NAT 2) experience toxicity. Drugs metabolized by acetylation include Hydralazine, Isoniazid, Procainamide, Sulfonamides, and Dapsone (mnemonic: HIPS Dance), all of which can cause drug-induced SLE. G-6-PD deficiency leads to hemolysis when patients are exposed to drugs like Dapsone, Methylene blue, Antimalarials (Primaquine), Nalidixic acid, Nitrofurantoin, Isoniazid, or Sulfonamides (mnemonic: Dr. MANIS).
Other polymorphisms include CYP2C19 affecting clopidogrel, CYP2C9 and VKORC1 affecting warfarin, and CYP2D6 affecting psychiatric drug toxicity. Malignant